Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Induction TPF followed by Cetuximab-RT vs CRT in HNSCC
NCT01233843Phase 3Completed
- Sponsor
- GORTEC
- Start
- May 2009
- Primary completion
- Nov 2018
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cetuximab and docetaxel in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by GORTEC. Primary endpoint: Complete response rate of the treatment at 2 years. Started May 2009; status: completed.
02
Drugs
cetuximabdocetaxel
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT01233843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01233843.